Asset Details
Do you wish to reserve the book?
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Do you wish to request the book?
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
2020
Overview
Peripheral neurotoxicity is a debilitating condition that afflicts up to 90% of patients with colorectal cancer receiving oxaliplatin-containing therapy. Although emerging evidence has highlighted the importance of various solute carriers to the toxicity of anticancer drugs, the contribution of these proteins to oxaliplatin-induced peripheral neurotoxicity remains controversial. Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity. The relevance of this transport system was verified in transporter-deficient rats as a secondary model organism, and translational significance of preventive strategies was demonstrated in preclinical models of colorectal cancer. These studies suggest that pharmacological targeting of OCT2 could be exploited to afford neuroprotection in cancer patients requiring treatment with oxaliplatin.
Publisher
American Society for Clinical Investigation
Subject
/ Animals
/ Cancer
/ Female
/ Genetically modified organisms
/ Male
/ Mice
/ Neurons
/ Neurotoxicity Syndromes - genetics
/ Neurotoxicity Syndromes - metabolism
/ Neurotoxicity Syndromes - pathology
/ Organic Cation Transporter 2 - genetics
/ Organic Cation Transporter 2 - metabolism
/ Oxaliplatin - adverse effects
/ Oxaliplatin - pharmacokinetics
/ Proteins
/ Rats
